What is HC Wainwright’s Forecast for Erasca FY2025 Earnings?

Erasca, Inc. (NASDAQ:ERAS) – HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Erasca in a note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.44) for the year, up from their previous forecast of ($0.48). The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s Q4 2025 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.26) EPS.

ERAS has been the topic of several other reports. Morgan Stanley reiterated an “equal weight” rating and set a $2.00 target price (down from $4.00) on shares of Erasca in a research report on Monday, August 18th. Guggenheim raised their price target on shares of Erasca from $3.00 to $5.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research note on Wednesday, October 8th. Stifel Nicolaus set a $6.00 target price on Erasca in a report on Thursday, November 6th. Finally, Wall Street Zen raised Erasca from a “sell” rating to a “hold” rating in a research note on Sunday, September 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

Erasca Trading Down 0.3%

ERAS opened at $2.86 on Monday. The stock has a market cap of $811.41 million, a PE ratio of -6.36 and a beta of 1.19. Erasca has a 1 year low of $1.01 and a 1 year high of $3.30. The stock’s 50 day simple moving average is $2.23 and its 200-day simple moving average is $1.73.

Erasca (NASDAQ:ERAS) last released its earnings results on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11).

Institutional Investors Weigh In On Erasca

Hedge funds have recently added to or reduced their stakes in the stock. Cerity Partners LLC acquired a new position in shares of Erasca during the first quarter worth approximately $49,000. CWM LLC raised its position in Erasca by 1,907.2% in the 1st quarter. CWM LLC now owns 36,250 shares of the company’s stock worth $50,000 after purchasing an additional 34,444 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Erasca in the 1st quarter worth approximately $136,000. TD Asset Management Inc lifted its holdings in Erasca by 6.3% during the 1st quarter. TD Asset Management Inc now owns 256,032 shares of the company’s stock worth $351,000 after buying an additional 15,286 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in Erasca by 123.1% in the 1st quarter. XTX Topco Ltd now owns 123,501 shares of the company’s stock valued at $169,000 after buying an additional 68,140 shares during the last quarter. Institutional investors own 67.78% of the company’s stock.

Erasca Company Profile

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.